Wegovy For Weight Loss: What it is, How it works, Uses, Benefits, Dosage, and Safety Guide

Wegovy is a once-weekly injectable prescription medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved by the U.S. Food and Drug Administration for chronic weight management in adults and adolescents aged 12 years and older with obesity, and for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Wegovy is administered using a pre-filled single-dose pen alongside a reduced-calorie diet and increased physical activity. It is the first GLP-1 receptor agonist licensed specifically for chronic weight management, at a once-weekly subcutaneous dose. Wegovy is not approved for type 2 diabetes and should not be combined with any other semaglutide-containing product or another GLP-1 receptor agonist.

Wegovy contains semaglutide, a long-acting synthetic analogue of the naturally occurring incretin hormone GLP-1. The molecule has been modified to resist degradation by the enzyme dipeptidyl peptidase-4 and to bind albumin in the bloodstream, which extends its half-life sufficiently to allow once-weekly dosing. By activating GLP-1 receptors throughout the body, semaglutide produces a coordinated effect on appetite, satiety, and metabolism that supports clinically meaningful weight reduction.

In the central nervous system, particularly the hypothalamus and brainstem, GLP-1 receptor activation modulates appetite-regulating neural circuits, increasing satiety, reducing hunger, and shifting food preference away from high-calorie items. In the gastrointestinal tract, semaglutide slows gastric emptying, contributing to fullness and reducing caloric intake. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon, which is why Wegovy also improves glycaemic parameters in people with concurrent type 2 diabetes. The cardiovascular benefit in adults with established cardiovascular disease reflects a combination of weight reduction, lower blood pressure, improved lipids, anti-inflammatory vascular effects, and direct cardiometabolic effects beyond weight loss alone.

Wegovy is not an appetite suppressant in the conventional sense, nor a metabolic stimulant. It is a hormonal therapy that recalibrates satiety signalling, so patients typically eat smaller portions, feel full sooner, and experience reduced food preoccupation. Treatment is initiated at a low dose and escalated over 16 weeks to a maintenance dose of 2.4 mg once weekly to improve gastrointestinal tolerability.

Wegovy has the following approved uses:

In adults:

• As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:
• A body mass index (BMI) of 30 kg/m² or higher, or
• A BMI of 27 kg/m² or higher with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidaemia.
• To reduce the risk of major adverse cardiovascular events (including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight.

In adolescents:

For chronic weight management, alongside lifestyle changes, in adolescents aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex.

Wegovy is not used for:

• Type 2 diabetes mellitus
• Type 1 diabetes
• Short-term or cosmetic weight loss

The principal benefits of Wegovy include:

• Sustained, clinically meaningful weight reduction in adults and adolescents living with obesity or overweight.
• Improvements in waist circumference supporting reductions in central adiposity.
• Better blood pressure and lipid parameters contribute to improved overall cardiometabolic health.
• Improved glycaemic control in individuals with prediabetes or type 2 diabetes.
• Reduction in the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, addressing a downstream consequence of excess adiposity rather than weight alone.
• Meaningful BMI reductions in adolescents, when combined with lifestyle support, outcomes that are often difficult to achieve through diet and exercise alone.
• Once-weekly dosing via a pre-filled pen, which supports long-term adherence and straightforward self-administration.

Wegovy is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day, with or without food. The injection can be given in the abdomen, thigh, or upper arm, and sites should be rotated with each dose. Treatment follows a structured 16-week dose-escalation schedule designed to improve gastrointestinal tolerability. The starting dose is 0.25 mg once weekly for four weeks, increased to 0.5 mg once weekly for four weeks, then 1 mg once weekly for four weeks, then 1.7 mg once weekly for four weeks, and finally to the maintenance dose of 2.4 mg once weekly.

Each pen is single-use and disposable. Pens should be stored in a refrigerator at 2°C to 8°C and not frozen; once in use, they may be kept at room temperature below 30°C for a limited period as specified in the medication guide.

NOTE: "The dosage of Wegovy for weight loss for each person varies based on their weight, desired outcome, and current health status. One must never self-administer this medication unless recommended by one's doctor."

Common side effects of Wegovy include:

• Gastrointestinal: Nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia (indigestion), eructation (belching or burping), flatulence, and gastroenteritis (inflammation of the stomach & intestines due to bacteria or viruses)
• General: Headache, fatigue, and dizziness
• Metabolic: Hypoglycaemia (low blood sugar levels), especially in people with type 2 diabetes.
• Digestive: Gastroesophageal reflux disease (GERD).
• Local: Discomfort, itching or redness at the injection site

Serious adverse reactions (uncommon, but require prompt medical attention):

• Acute pancreatitis, which may present as severe, persistent abdominal pain that may radiate to the back, with or without vomiting.
• Acute gallbladder disease, including cholelithiasis and cholecystitis, is particularly associated with rapid or substantial weight loss.
• Acute kidney injury usually in the context of dehydration arising from gastrointestinal side effects.
• Hypersensitivity reactions, including anaphylaxis and angioedema (rare but possible).
• Pulmonary aspiration is reported in patients undergoing procedures requiring sedation or general anaesthesia.
• Worsening of diabetic retinopathy, observed during rapid improvement of glycaemic control.
• Suicidal ideation and behaviour, reported in patients treated with weight-management products including Wegovy; patients should be monitored for emerging mood changes.

Boxed warning:

• Wegovy carries a boxed warning issued by the US FDA regarding the risk of thyroid C-cell tumours, based on findings observed in rodent studies. Whether these findings translate to humans has not been determined.

Contraindications (Wegovy must not be used in the following cases):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to semaglutide
• Treatment should be discontinued at least two months before a planned pregnancy due to the long half-life of semaglutide
• Human data on semaglutide in breast milk are limited; therefore, benefits and risks should be weighed individually

Use with caution in patients with:

• A history of pancreatitis (Discontinue if pancreatitis is suspected, and do not restart if confirmed)
• Severe gastrointestinal disease or gastroparesis
• Diabetic retinopathy
• Renal impairment

Planning on undergoing elective procedures with sedation or general anaesthesia (it can delay gastric emptying, increasing the risk of pulmonary aspiration)

Drug interactions to be aware of:

• Wegovy with insulin (SEVERE): It carries a significant risk of hypoglycaemia (low blood sugar levels). Insulin dose reductions are commonly required when initiating treatment.
• Wegovy with Sulfonylureas (SEVERE): Dose reduction is often necessary to limit hypoglycaemia.
• Wegovy with other semaglutide-containing products or GLP-1 receptor agonists (SEVERE): It must not be combined as it offers no added benefit and increases the risk of adverse effects.
• Wegovy with other narrow therapeutic index oral medications (such as warfarin & levothyroxine): Absorption may be altered due to delayed gastric emptying. Clinical effect or relevant laboratory values should be monitored.

Food, drink, and lifestyle considerations:

• No specific food restrictions apply.
• Large or high-fat meals may increase nausea, especially when the dosage is increased. Eat smaller portions slowly to prevent this condition.
• Alcohol may increase the risk of pancreatitis and worsen gastrointestinal side effects. Limit the use to reduce the risk.

Missed dose guidance:

• If the next scheduled dose is more than two days away, take the missed dose as soon as possible.
• If less than two days remain, skip the missed dose and take the next one at the regular time.
• Never take two doses on the same day.
• If more than two consecutive doses are missed, consult the prescribing clinician.

In the event of overdose:

• The most likely outcome is severe and prolonged gastrointestinal symptoms, especially nausea and vomiting.
• Risk of hypoglycaemia increases if Wegovy is combined with insulin or sulfonylureas.
• Supportive care, including attention to hydration and electrolytes.
• Symptoms may persist for several days, given the long half-life of semaglutide.
• Patients should contact a poison control centre or seek emergency care promptly.

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
2. https://www.ncbi.nlm.nih.gov/books/NBK603723/
3. https://medlineplus.gov/druginfo/meds/a618008.html
4. https://www.ncbi.nlm.nih.gov/books/NBK501922/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
6. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563